Ranibizumab could improve vision for Age Releted Macular Degeneration patents

In a randomized clinical trial(phase III) scientists of Johans Hopkins, have found that Lucentis's Ranibizumab is superior than Photodynamic therapy with verteporfin Photodynamic therapy (PDT), while treating age related neovascular Macular Degeneration. The report was published  in the January issue of Archives of Ophthalmology.

Researchers observed that after a 12 months treatment with both the therapy shows  significant differences, there were a greater improvements in self-reported vision-related function for patients given a low dose (P=0.002) and a high dose (P<0.001) of ranibizumab, compared with those treated with photodynamic therapy. The mean improvements on the visual function questionnaire of 5.9 and 8.1 points for the low and high doses of ranibizumab, respectively. Whereas the photodynamic therapy group improved by only 2.2 points.

Scientists also observed that though it takes 12 months for the treatment  effect to come out  but the benefits with  ranibizumab lasts for almost two years.

A previous report of the same study in the Oct. 5, 2006, issue of the New England Journal of Medicine showed that ranibizumab prevented a greater proportion of patients from losing 15 letters of visual acuity or more.

The superiority of ranibizumab remained at 24 months with improvements of 5.0 and 5.8 points in overall score with the low and high doses, respectively, which were significantly greater than the nonsignificant -0.3-point change with photodynamic therapy.

Source: medpage Today

Related?

Leave a Reply


Protected by Comment Guard Pro